140 related articles for article (PubMed ID: 23749639)
1. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes.
Yang J; Wang J; Chen K; Guo G; Xi R; Rothman PB; Whitten D; Zhang L; Huang S; Chen JL
Cancer Res; 2013 Aug; 73(15):4898-908. PubMed ID: 23749639
[TBL] [Abstract][Full Text] [Related]
2. eIF4B is a convergent target and critical effector of oncogenic Pim and PI3K/Akt/mTOR signaling pathways in Abl transformants.
Chen K; Yang J; Li J; Wang X; Chen Y; Huang S; Chen JL
Oncotarget; 2016 Mar; 7(9):10073-89. PubMed ID: 26848623
[TBL] [Abstract][Full Text] [Related]
3. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
4. The over-expression of Pim-2 promote the tumorigenesis of prostatic carcinoma through phosphorylating eIF4B.
Ren K; Gou X; Xiao M; Wang M; Liu C; Tang Z; He W
Prostate; 2013 Sep; 73(13):1462-9. PubMed ID: 23813671
[TBL] [Abstract][Full Text] [Related]
5. AGC kinases regulate phosphorylation and activation of eukaryotic translation initiation factor 4B.
van Gorp AG; van der Vos KE; Brenkman AB; Bremer A; van den Broek N; Zwartkruis F; Hershey JW; Burgering BM; Calkhoven CF; Coffer PJ
Oncogene; 2009 Jan; 28(1):95-106. PubMed ID: 18836482
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic E17K mutation in the pleckstrin homology domain of AKT1 promotes v-Abl-mediated pre-B-cell transformation and survival of Pim-deficient cells.
Guo G; Qiu X; Wang S; Chen Y; Rothman PB; Wang Z; Chen Y; Wang G; Chen JL
Oncogene; 2010 Jul; 29(26):3845-53. PubMed ID: 20440266
[TBL] [Abstract][Full Text] [Related]
7. Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.
Chen JL; Limnander A; Rothman PB
Blood; 2008 Feb; 111(3):1677-85. PubMed ID: 18042805
[TBL] [Abstract][Full Text] [Related]
8. Pim kinase substrate identification and specificity.
Peng C; Knebel A; Morrice NA; Li X; Barringer K; Li J; Jakes S; Werneburg B; Wang L
J Biochem; 2007 Mar; 141(3):353-62. PubMed ID: 17234686
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
10. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity.
Shahbazian D; Roux PP; Mieulet V; Cohen MS; Raught B; Taunton J; Hershey JW; Blenis J; Pende M; Sonenberg N
EMBO J; 2006 Jun; 25(12):2781-91. PubMed ID: 16763566
[TBL] [Abstract][Full Text] [Related]
11. [Synergistic role of JAK/STAT5 and PI3K/AKT signaling pathways in regulating eIF4B in acute leukemia].
Ma Y; Li T; Feng R; Guo G; Pan Q; Li J; Chen J
Sheng Wu Gong Cheng Xue Bao; 2020 Nov; 36(11):2413-2423. PubMed ID: 33244935
[TBL] [Abstract][Full Text] [Related]
12. AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Zhou LL; Zhao Y; Ringrose A; DeGeer D; Kennah E; Lin AE; Sheng G; Li XJ; Turhan A; Jiang X
J Exp Med; 2008 Oct; 205(11):2657-71. PubMed ID: 18936234
[TBL] [Abstract][Full Text] [Related]
13. Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
Xie S; Wang Y; Liu J; Sun T; Wilson MB; Smithgall TE; Arlinghaus RB
Oncogene; 2001 Sep; 20(43):6188-95. PubMed ID: 11593427
[TBL] [Abstract][Full Text] [Related]
14. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
15. Pim kinase-dependent inhibition of c-Myc degradation.
Zhang Y; Wang Z; Li X; Magnuson NS
Oncogene; 2008 Aug; 27(35):4809-19. PubMed ID: 18438430
[TBL] [Abstract][Full Text] [Related]
16. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells.
Hoover RR; Gerlach MJ; Koh EY; Daley GQ
Oncogene; 2001 Sep; 20(41):5826-35. PubMed ID: 11593388
[TBL] [Abstract][Full Text] [Related]
17. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
[TBL] [Abstract][Full Text] [Related]
18. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels.
Morishita D; Katayama R; Sekimizu K; Tsuruo T; Fujita N
Cancer Res; 2008 Jul; 68(13):5076-85. PubMed ID: 18593906
[TBL] [Abstract][Full Text] [Related]
19. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
20. Constitutively activated FLT3 phosphorylates BAD partially through pim-1.
Kim KT; Levis M; Small D
Br J Haematol; 2006 Sep; 134(5):500-9. PubMed ID: 16869825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
